Abstract:Alzheimer's disease (AD) is a heterogeneous neurodegenerative disease. Recent studies employing microRNA-seq and genome-wide sequencing have identified some non-coding RNAs that are influentially involved in AD pathogenesis. Non-coding RNAs can compete with other endogenous RNAs by microRNA response elements (MREs) and manipulate biological processes, such as tumorigenesis. However, only a few non-coding RNAs have been reported in the pathogenesis of AD. In this study, we constructed the first competing endogenous RNA (ceRNA) network leveraging whole transcriptome sequencing and a previously studied microRNA-seq of APPswe/PS1ΔE9 transgenic mice. The underlying mechanisms for the involvement of ceRNA in AD were validated using the Dual Luciferase Reporter Assay, detection of transcription levels by quantitative RT-PCR and translation levels by Western blotting, and morphological examination in primary cultured neurons. In the ceRNA network, four lncRNAs (C030034L19Rik, Rpph1, A830012C17Rik, and Gm15477) and five miRNAs (miR-182-5p, miR-330-5p, miR-326-3p, miR-132-3p, and miR-484) are enriched in nine pathways and an AD-related gene pool. Among them, Ribonuclease P RNA component H1 (Rpph1) is upregulated in the cortex of APPswe/PS1ΔE9 mice compared to wild type controls. Rpph1 binds to miR326-3p/miR-330-5p and causes the release of their downstream target Cdc42, which leads to CDC42 upregulation. This effect was disrupted upon mutation of the MRE on Rpph1. Moreover, overexpression of Rpph1 increased dendritic spine density in primary cultured hippocampal pyramidal neurons, whereas knocking down of Rpph1 had the reverse effect. In conclusion, Rpph1 modulates CDC42 expression level in a ceRNA-dependent manner, which may represent a compensatory mechanism in the early stage of the AD pathogenesis.

[Research Advances in the Association Between Alzheimer's Disease and Double-Stranded RNA-Dependent Protein Kinase]

Circular RNA aptamers ameliorate AD-relevant phenotypes by targeting PKR

Advances with RNA Interference in Alzheimer&rsquo;s Disease Research

The Recent Updates of Therapeutic Approaches Against Aβ for the Treatment of Alzheimer's Disease

PKCδ Serves As a Potential Biomarker and Therapeutic Target for Microglia-Mediated Neuroinflammation in Alzheimer's Disease

Inhibition of PKCδ reduces amyloid-β levels and reverses Alzheimer disease phenotypes

PKR downregulation prevents neurodegeneration and β-amyloid production in a thiamine-deficient model

PARP16-Mediated Stabilization of Amyloid Precursor Protein Mrna Exacerbates Alzheimer’s Disease Pathogenesis

Exploring the Frontier: Antisense Long Non-Coding RNAs As Key Regulators in Alzheimer's Disease.

Non-Coding RNAs as Novel Regulators of Neuroinflammation in Alzheimer's Disease

MicroRNAs: Pioneering Regulators in Alzheimer’s Disease Pathogenesis, Diagnosis, and Therapy

Rpph1 Upregulates CDC42 Expression and Promotes Hippocampal Neuron Dendritic Spine Formation by Competing with Mir-330-5p.

Delta-Secretase Phosphorylation by SRPK2 Enhances Its Enzymatic Activity, Provoking Pathogenesis in Alzheimer's Disease

MicroRNAs: pioneering regulators in Alzheimer's disease pathogenesis, diagnosis, and therapy

Non-coding RNAs in Regulation of Protein Aggregation and Clearance Pathways: Current Perspectives Towards Alzheimer's Research and Therapy

Analysis of the role of Purα in the pathogenesis of Alzheimer's disease based on RNA-seq and ChIP-seq

P2‐312: the Rps23r1 Gene Family Regulates Alzheimer's Beta‐amyloid Generation and Tau Phosphorylation

Targeting protein kinases for the treatment of Alzheimer's disease: Recent progress and future perspectives

β2 Adrenergic Receptor, Protein Kinase A (PKA) and c-Jun N-terminal Kinase (JNK) Signaling Pathways Mediate Tau Pathology in Alzheimer Disease Models

The Regulation of Micrornas in Alzheimer's Disease

Novel Insights into RIPK1 As a Promising Target for Future Alzheimer’s Disease Treatment